Cancer center support grant

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Project Description:
Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.
 
Project Terms:
ambulatory care area base basic science cancer biology cancer center support grant cancer control categories cell behavior clinical clinical research core facility design detection development diagnosis experimental pathology funding genomics image inpatients laboratories malignant neoplasms memorial sloan-kettering cancer center mission molecular structure nci center for cancer research outcome patient oriented research patient population pilot projects population sciences prevention programs radiation recruitment activity regulation research research facility research personnel research training risk science services standard care stem cell biology survivorship therapeutic training programs transplantation immunology vision work
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
Organization: Sloan-Kettering Inst Can Research, United States, New York, NEW YORK
Principal Investigators (PI): Thompson Craig B, US
 
Project Categories:
Natural Sciences
 
Other Information:
Fiscal Year: 1997
Project Start Date: 20 January 1997
Project End Date: 31 December 2019
Project program: Center Core Grants
 
Project Funding Information:
Funding Mechanism: Research Centers
Year Funding Organization Total Funding, $
2014 NIH - National Cancer Institute $12,352,942
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Title FY Funding
X-ray 2014 $271886
Biostatistic 2014 $944198
Microchemistry & proteomics 2014 $373324
Pathology 2014 $533238
Organic sythesis 2014 $321306
High throughput screening 2014 $538362
Melecular cytogenetics 2014 $215572
Research pharmacy 2014 $206350
Web survey core 2014 $125242
Behavioral research 2014 $62019
Radiochemisty 2014 $357996
Center of com med and pathology 2014 $2450521
Flow cytometry 2014 $362498
Genomics 2014 $734379
Animal imaging 2014 $247784
Gene transfer 2014 $369893
Developmental funds 2014 $1421601
Mouse genetics 2014 $901798
Antitumor 2014 $222125
Monoclonal antibody 2014 $282755
Planning & evaluation 2014 $88851
Melecular cytology 2014 $460563
Bioinfomatics 2014 $860681
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Project Title Organization FY Funding
Cancer Center Support GrantSloan-Kettering Inst Can Research2017$125,746
Cancer Center Support GrantSloan-Kettering Inst Can Research2017$291,054
Cancer Center Support GrantSloan-Kettering Inst Can Research2017$12,352,942
Cancer Center Support GrantSloan-Kettering Inst Can Research2017$40,000
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$12,352,942
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$124,656
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$250,000
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$59,999
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$200,000
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$500,000
Cancer Center Support GrantSloan-Kettering Inst Can Research2016$999,291
Cancer Center Support GrantSloan-Kettering Inst Can Research2015$12,352,942
Cancer Center Support GrantSloan-Kettering Inst Can Research2015$234,533
Cancer Center Support GrantSloan-Kettering Inst Can Research2015$55,649
Cancer Center Support GrantSloan-Kettering Inst Can Research2015$20,000
Cancer Center Support GrantSloan-Kettering Inst Can Research2014$74,197
Cancer Center Support GrantSloan-Kettering Inst Can Research2014$115,999
Cancer Center Support GrantSloan-Kettering Inst Can Research2014$12,352,942
Cancer Center Support GrantSloan-Kettering Inst Can Research2013$18,456
Cancer Center Support GrantSloan-Kettering Inst Can Research2013$238,405
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Title Journal Year Country Rel
Diastereoselective Synthesis of Highly Substituted Tetrahydrofurans by Pd-Catalyzed Tandem Oxidative Cyclization-Redox Relay Reactions Controlled by Intramolecular Hydrogen Bonding. J Org Chem 2017 united states
Moderators of the effects of meaning-centered group psychotherapy in cancer survivors on personal meaning, psychological well-being, and distress. Support Care Cancer 2017 germany
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol 2017 united states
A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning. Phys Med Biol 2017 england
A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecol Oncol 2017 united states
Haploinsufficiency of the Transcription Factor Ets-1 Is Renoprotective in Dahl Salt-Sensitive Rats. J Am Soc Nephrol 2017 united states
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017 england
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev 2017 england
ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 2017 england
Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity. J Exp Med 2017 united states
Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cell Signal 2017 england
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. Clin Cancer Res 2017 united states
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell 2017 united states
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol 2017 switzerland
Initial performance studies of a wearable brain positron emission tomography camera based on autonomous thin-film digital Geiger avalanche photodiode arrays. J Med Imaging (Bellingham) 2017 united states
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-? inhibitor therapy and literature review. Ann Diagn Pathol 2017 united states
Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. J Clin Oncol 2017 united states
Mapping genetic variations to three-dimensional protein structures to enhance variant interpretation: a proposed framework. Genome Med 2017 england
Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia 2017 united states
Biomarker Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? Clin Cancer Res 2017 united states
Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. J Thorac Cardiovasc Surg 2017 united states
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. Cancer Res 2017 united states
Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. Clin Nucl Med 2017 united states
Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Aff (Millwood) 2017 united states
Structure and reconstitution of yeast Mpp6-nuclear exosome complexes reveals that Mpp6 stimulates RNA decay and recruits the Mtr4 helicase. Elife 2017 england
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol 2017 united states
Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study. J Natl Cancer Inst Monogr 2017 united states
Adapting Meaning-Centered Psychotherapy for the palliative care setting: Results of a pilot study. Palliat Med 2017 england
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur Urol 2017 switzerland
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget 2017 united states
Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Ann Surg Oncol 2017 united states
Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. Histopathology 2017 england
Educating front-line clinicians about antimicrobial resistance. Lancet Infect Dis 2017 united states
Ontogenetic establishment of order-specific nuclear organization in the mammalian thalamus. Nat Neurosci 2017 united states
The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. Ann Surg Oncol 2017 united states
Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY) 2017 united states
Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia 2017 england
Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s. BMC Med Inform Decis Mak 2017 england
Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. J Natl Cancer Inst 2017 united states
Treatment decisions and employment of breast cancer patients: Results of a population-based survey. Cancer 2017 united states
The potential of organoids in urological cancer research. Nat Rev Urol 2017 england
A Practical Framework for Understanding and Reducing Medical Overuse: Conceptualizing Overuse Through the Patient-Clinician Interaction. J Hosp Med 2017 united states
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 2017 united states
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 2017 united states
Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases. Am J Surg Pathol 2017 united states
Surgeon Attitudes and Use of MRI in Patients Newly Diagnosed with Breast Cancer. Ann Surg Oncol 2017 united states
Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS One 2017 united states
Distance in cancer gene expression from stem cells predicts patient survival. PLoS One 2017 united states
Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav 2017 united states
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. Palliat Support Care 2017 england
Implementation of Dynamically Updated Prediction Models at the Point of Care at a Major Cancer Center: Making Nomograms More Like Netflix. Urology 2017 united states
Isolated pink papule on the chest. Dermatol Pract Concept 2017 united states
Full Information Maximum Likelihood Estimation for Latent Variable Interactions With Incomplete Indicators. Multivariate Behav Res 2017 united states
Applications of pHLIP Technology for Cancer Imaging and Therapy. Trends Biotechnol 2017 england
Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One 2017 united states
Specimen Identification Errors in Breast Biopsies: Age Matters. Report of Two Near-Miss Events and Review of the Literature. Breast J 2017 united states
Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med 2017 united states
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist 2017 united states
Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 2017 united states
An integrated model for detecting significant chromatin interactions from high-resolution Hi-C data. Nat Commun 2017 england
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers? Transl Lung Cancer Res 2017 china
Investigation of patterns of nodal metastases in BRAF mutant lung cancer. Lung Cancer 2017 ireland
Depressive symptoms predict cancer caregivers' physical health decline. Cancer 2017 united states
Efficacy of meaning-centered group psychotherapy for cancer survivors: a randomized controlled trial. Psychol Med 2017 england
A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules. Int J Cancer 2017 united states
Validation of Clinical Tools for Vaginal and Vulvar Symptom Assessment in Cancer Patients and Survivors. J Sex Med 2017 netherlands
Polycomb Responds to Low Levels of Transcription. Cell Rep 2017 united states
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys 2017 united states
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 2017 united states
Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). J Am Chem Soc 2017 united states
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecol Oncol 2017 united states
Acceptability of a Salon-Based Intervention to Promote Colonoscopy Screening Among African American Women. Health Educ Behav 2017 united states
Advances in the management of conjunctival melanoma. Surv Ophthalmol 2017 united states
Left-lateralization of resting state functional connectivity between the presupplementary motor area and primary language areas. Neuroreport 2017 england
BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 2017 united states
Proportion of cancer in a Middle eastern country attributable to established risk factors. BMC Cancer 2017 england
Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci U S A 2017 united states
Will the circle be unbroken: specific mutations in the yeast Sm protein ring expose a requirement for assembly factor Brr1, a homolog of Gemin2. RNA 2017 united states
Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer 2017 england
Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet 2017 united states
Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma. JAMA Dermatol 2017 united states
Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis 2017 england
Diagnostic dilemmas and pitfalls in ThinPrep® cytology of breast fine needle aspiration biopsy:: Report of Six Cases with Histological Correlates. Diagn Cytopathol 2017 united states
Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. Breast 2017 netherlands
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2017 netherlands
Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. Clin Radiol 2017 england
Organizational Strategies for Building Capacity in Evidence-Based Oncology Nursing Practice: A Case Report of an Australian Tertiary Cancer Center. Nurs Clin North Am 2017 united states
Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene 2017 england
The MukB-topoisomerase IV interaction is required for proper chromosome compaction. J Biol Chem 2017 united states
A Communication Training Program to Encourage Speaking-Up Behavior in Surgical Oncology. AORN J 2017 united states
Checkpoint inhibition and melanoma: Considerations in treating the older adult. J Geriatr Oncol 2017 netherlands
Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. J Clin Endocrinol Metab 2017 united states
Prospective Trial Evaluating the Surgical Anastomosis at One-Year Colorectal Cancer Surveillance: CT Colonography Versus Optical Colonoscopy and Implications for Patient Care. Dis Colon Rectum 2017 united states
Tanning and Teens: Is Indoor Exposure the Tip of the Iceberg? Cancer Epidemiol Biomarkers Prev 2017 united states
Urothelial neoplasms in pediatric and young adult patients: A large single-center series. J Pediatr Surg 2017 united states
Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation. JAAD Case Rep 2017 united states
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer 2017 ireland
Dissecting Glioma Invasiveness in a 3D-Organotypic Model. Trends Mol Med 2017 england
Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology 2017 england
Impact of Bilateral Prophylactic Mastectomy and Immediate Reconstruction on Health-Related Quality of Life in Women at High Risk for Breast Carcinoma: Results of the Mastectomy Reconstruction Outcomes Consortium Study. Ann Surg Oncol 2017 united states
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Title Year
Methods of detection of cancer using peptide profiles 2006
Cloning and uses of the genetic locus bcl-6 1989
Ma family polypeptides and anti-Ma antibodies 1988
Ganglioside-KLH conjugate vaccines plus QS-21 1987
Ganglioside-KLH conjugate vaccines plus OS-21 1987
Ganglioside-KLH conjugate vaccines plus QS-21 1987
Ganglioslide-KLH conjugate vaccine plus QS-21 1987
Purified human ceramide-activated protein kinase 1986
Ganglioside-KLH conjugate vaccine plus QS-21 1985
Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents 1985
Alkyl N-[3-(acridin-9-yl)amino-5-hydroxymethyl] phenylcarbamates 1985
Pigmentation associated, differentiation antigen of human melanoma and autologous antibody 1985
Monoclonal antibodies to human lung cancers and method 1985
Synthetic compounds which bind to H. pylori, and uses thereof 1985
Process for preparing purified interleukin-2 1985
Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors 1985
Purified interleukin 2 1985
Method to detect sensitivity to alpha-interferon therapy 1985
Monoclonal antibody panel for blood group a antigen 1985
Derivatives of chrysophanol as topoisomerase II inhibitors 1985
Synthesis of 8H-3A-aza-cyclopenta [A ]indenes and 5,10-dihydropyrrolo[1,2-B]isoquinolines derivatives and their use as antitumor therapeutic agents 1985
Monoclonal antibodies selective for prostate cancer 1985
Synthesis of glycoconjugates of the lewis y epitope and uses thereof 1985
Uses of interleukin-2 1985
Cloning and uses of the genetic locus BCL-6 1985
Derivatives of chryosphanol 1985
Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof 1985
Synthesis of glycoconjugates of the globo-H epitope and uses thereof 1985
5-(9-acridinylamino)-toluidine compounds 1985
Ma family polypeptides and anti-Ma antibodies 1985
Synthesis of 4H-benzo[D]pyrrolo[1,2-A]thiazoles and indolizino[6,7-b]indole derivatives and their use as antitumor therapeutic agents 1985
Interleukin-2 dependent cytotoxic T-cell clones 1985
Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof 1985
Cloning and uses of the genetic locus bcl-6 1985
Monoclonal antibodies against melanocytes 1985
Highly purified interleukin-2 and method 1985
Human monoclonal antibodies to cell surface antigens 1985
Cloning and uses of the genetic locus BCL-6 1985
Therapeutic use of hypervariable region of monoclonal antibody M195 and constructs thereof 1985
Monoclonal antibodies to cell surface antigens of human malignant melanoma 1985
Human monoclonal antibodies to cancer cells 1985
System and process for microfluidics-based automated chemistry 1985
Monoclonal antibodies selective for prostate cancer and diagnostic immunoassay for prostate cancer 1985
Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents 1985
Antigen recognized by patients with antibody associated cerebellar degeneration, DNA encoding same and uses thereof 1985
Human monoclonal antibodies from lymphocytes of patients with malignant melanoma 1985
6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives 1985
Antigen recognized by patients with antibody associated paraneoplastic cerebellar degeneration, DNA encoding same and uses thereof 1985
Synthesis of the breast tumor-associated antigen defined by monoclonal antibody MBr1 and uses thereof 1985
Highly purified human interleukin 2 and method 1985
Synthesis of glycoconjugates of the lewis Y epitope and uses thereof 1985
3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as anticancer agents 1985
Hydroxamic acid compounds and methods of use thereof 1985
Methods for detecting minimum residual disease 1985
Synthesis of thiohydantoins 1985
Synthesis of thiohydantoins 1985
Synthesis of thiohydantoins 1985
Project Title: Cancer center support grant
Project Number: 2P30CA008748-48
Project web address: Follow on NIH
 
Title Phase Year
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2 2014
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Phase 2 2014
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors Phase 2 2003
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic Phase 1 1995
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Phase 1/Phase 2 1995
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Phase 1 1995
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Phase 1/Phase 2 1995
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1 1995
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Phase 1 1995
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Phase 1/Phase 2 1995
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Phase 1/Phase 2 1995
Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Phase 1 1995
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Phase 3 1985
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Phase 2 1985
Nivolumab in Treating Patients With High-Risk Non-Metastatic Kidney Cancer Phase 1 1985
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2 1985
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer Phase 1 1985
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer Phase 3 1985
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer N/A 1985
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Phase 2 1985
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors Phase 1 1985
Depression Screening in Patients With Lung Cancer N/A 1985
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Phase 2 1985
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Phase 2 1985
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Phase 1/Phase 2 1985
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Phase 2 1985
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer N/A 1985
Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions N/A 1985
Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women N/A 1985
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 2 1985
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer Phase 1 1985
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Phase 2 1985
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Phase 2 1985
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia Phase 2 1985
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery Phase 2/Phase 3 1985
CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy Phase 2 1985
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed Phase 2 1985
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer Phase 1 1985
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin Phase 2 1985
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Phase 1/Phase 2 1985
Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer Phase 1 1985
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Phase 1 1985
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma Phase 2 1985
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer Phase 1 1985
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Phase 2 1985
Risk Factors for Endometrial Cancer in Black Women N/A 1985
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission Phase 2 1985
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia Phase 2 1985
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors Phase 1 1985
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Phase 1 1985
Multiple Therapies in Treating Patients With Advanced Neuroblastoma Phase 2 1985
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer N/A 1985
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma Phase 2 1985
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib Phase 2 1985
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Phase 2 1985
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Phase 2 1985
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer Phase 1 1985
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma Phase 1 1985
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Phase 2 1985
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer Phase 2 1985
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma Phase 2 1985
Combination Chemotherapy in Treating Patients With Bladder Cancer Phase 3 1985
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Phase 1 1985
Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Phase 2 1985
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma Phase 1/Phase 2 1985
Bortezomib in Treating Patients With Lymphoproliferative Disorders Phase 2 1985
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Phase 3 1985
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Phase 2 1985
Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer Phase 2 1985
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer Phase 1 1985
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Phase 2 1985
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Phase 1/Phase 2 1985
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1 1985
IMC-A12 in Treating Patients With Advanced Liver Cancer Phase 2 1985
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer N/A 1985
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Phase 2 1985
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Phase 2 1985
Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma Phase 1 1985
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners N/A 1985
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Phase 2 1985
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Phase 1/Phase 2 1985
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer Phase 1 1985
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Phase 2 1985
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy Phase 1 1985
PET Scan in Treating Patients With Metastatic Prostate Cancer N/A 1985
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Phase 2 1985
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Phase 2 1985
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Phase 2 1985
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Phase 2 1985
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Phase 2 1985
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer Phase 2 1985
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1 1985
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma Phase 2 1985
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Phase 2 1985
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase 1 1985
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma Phase 1 1985
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Phase 2 1985
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Phase 1 1985